Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis

European Journal of Neurology

Volumn 12, Issue 7, 2005, Pages 550-556

  Zorzon, Marino ^a,c   Zivadinov, R ^a,b   Locatelli, L ^a   Giuntini, D ^c   Toncic, M ^a   Bosco, A ^a   Nasuelli, D ^a   Bratina, A ^a   Tommasi, M A ^a   Rudick, R A ^d   Cazzato, G ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF TRIESTE   (Italy)

^d Mellen Center for MS   (United States)

Author keywords

Bone mineral density; Multiple sclerosis; Osteopenia; Osteoporosis; Steroids

Indexed keywords

METHYLPREDNISOLONE;

ADULT; AGE; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG PULSE THERAPY; FEMALE; FEMUR NECK; GENDER; HUMAN; LUMBAR SPINE; MALE; MENOPAUSE; MULTIPLE SCLEROSIS; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL;

ADULT; ANTI-INFLAMMATORY AGENTS; BONE DENSITY; BONE DISEASES, METABOLIC; FEMALE; FEMUR NECK; HUMANS; INJECTIONS, INTRAVENOUS; LUMBOSACRAL REGION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIPLE SCLEROSIS; OSTEOPOROSIS; SPINE; TIME;

EID: 21844463094     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.00988.x     Document Type: Article

References (21)

1. Beck RW (1999). A phase II study of IV methylprednisolone in secondary progressive MS. Neurology 52:896.
2. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R (1994). High dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 9:1097-1105.
3. Cosman F, Nieves J, Komar L et al. (1998). Fracture history and bone loss in patients with MS. Neurology 51:1161-1165.
4. Formica CA, Cosman F, Nieves J, Herbert J, Lindsay R (1997). Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use. Calcif Tissue Int 61:129-133.
5. Goodkin DE, Kinkel RP, Weinstock-Guttman B et al. (1998). A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 51:239-245.
6. Havrdova E, Tyblova M, Stepan J et al. (2002). Osteoporosis in multiple sclerosis patients treated with corticosteroids. Multiple Scler 8 (Suppl. 1):S79.
7. Hodgson SF (1990). Corticosteroid-induced Osteoporosis. Endocrinol Metab Clin North Am 19:95-111.
8. Kupersmith MJ, Kaufman D, Paty DW et al. (1994). Megadose corticosteroids in MS. Neurology 44:1-4.
9. Kurtzke JF (1983). Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33:1444-1452.
10. Lukert BP, Raisz LG (1990). Glucocorticoid-induced Osteoporosis: pathogenesis and management. Ann Intern Med 112:352-364.
11. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R (1994). High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44:1687-1692.
12. Oliveri RL, Valentino P, Russo C et al. (1998). Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 50:1833-1836.
13. Optic Neuritis Study Group (1997). The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Neurology 49:1404-1413.
14. Perez Castrillon JL, Cano-del Pozo M, Sanz-Izquierdo S, Velayos-Jimenez J, Dib-Wobakin W (2003). Bone mineral density in patients with multiple sclerosis: the effects of interferon. Rev Neurol 36:901-903.
15. Schwid SR, Goodman AD, Puzas JE, McDermott P, Mattson DH (1996). Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 53:753-757.
16. The WHO Study Group (1994) Assessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. World Health Organization, Geneva.
17. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000a). Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000.
18. Van Staa TP, Leufkens HGM, Abenhaim L, Begaud B, Zhang B, Cooper C (2000b). Use of oral corticosteroids in the United Kingdom. Q Med J 93:105-111.
19. Walsh LJ, Wong CA, Pringle M, Tattersfield AE (1996). Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. Br Med J 313:344-346.
20. Weinstock-Guttman B, Gallagher E, Baier M et al. (2004). Risk of bone loss in men with multiple sclerosis. Multiple Scler 10:170-175.
21. Zivadinov R, Rudick RA, De Masi R et al. (2001). Effects of IV methylprednisolone on brain atrophy in relapsing-remitting multiple sclerosis. Neurology 57:1239-1247.